TORONTO, June 2, 2017 /CNW/ - Dr. Ali Tehrani, President & Chief Executive Officer, Zymeworks Inc. (ZYME), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to close the market. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks Inc. commenced trading on Toronto Stock Exchange on May 3, 2017.
SOURCE TMX Group Limited
Share this article